 <b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	Application Number	10/718,955
	Filing Date	November 21, 2003
	First Named Inventor	Clayton H. Johnson et al.
	Art Unit	1645
	Examiner Name	Unknown
	Attorney Docket Number	55474-294389
Total Number of Pages in This Submission		

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): See Remarks
<b>Remarks</b> Express Mail Certificate EV 463 363 546 US; PTO/SB/08A Listing 147 References; 130 Non-U.S. Patent References (18-147); and Return Postcard.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm	Kilpatrick Stockton LLP		
Signature			
Printed Name	Cynthia B. Rothschild		
Date	8-2-2005	Reg. No.	47,040

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



08-03-05

IFW

## EXPRESS MAIL CERTIFICATE

"Express Mail" Label No. : EV 463 363 546 US

Serial No. : 10/718,955

Applicant(s) : Clayton H. Johnson et al.

Filing Date : November 21, 2003

Title : ***HISTOPLASMA CAPSULATUM CHITIN SYNTHASE  
SEQUENCES AND THEIR USE FOR DETECTION  
OF HISTOPLASMA CAPSULATUM AND  
HISTOPLASMOSIS***


Examiner : Unknown

Group Art Unit : 1645

Type of Document(s) : Express Mail Certificate;  
Transmittal Form (PTO/SB/21);  
Information Disclosure Statement (*in duplicate*);  
PTO/SB/08A listing 147 References;  
130 Non-U.S. Patent References (18-147); and  
Return Postcard

I hereby certify that the documents identified above are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and are addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date Mailed: August 2, 2005

 (signature)  
Amber C. Johnson



EV 463 363 546 US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Clayton H. Johnson et al.  
Serial No : 10/718,955  
Filed : November 21, 2003  
For : ***HISTOPLASMA CAPSULATUM CHITIN SYNTHASE  
SEQUENCES AND THEIR USE FOR DETECTION  
OF HISTOPLASMA CAPSULATUM AND  
HISTOPLASMOSIS***  
  
Examiner : Unknown  
Art Unit : 1645

---

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicants submit herewith on Form PTO/SB/08A a listing of 147 documents known to the Applicants and/or their attorney. Applicants respectfully request consideration of the cited documents and making the same of record in the prosecution of the above-identified application. In so doing, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the present application, or to establish that such references are not prior art. Pursuant to the Notice in the Official Gazette of August 5, 2003, wherein the Patent Office waived the requirements of 37 C.F.R. § 1.98(a)(2)(i), Applicants have not enclosed copies of the U.S. patent references. Copies of foreign or international documents, and non-patent literature (documents 18-147), are enclosed, numbered and labeled for identification purposes.


This statement should not be construed as a representation that more material information does not exist or that a search of the relevant art has been made. It is respectfully requested that the references listed on the attached form PTO/SB/08A be expressly considered by the Examiner, made of record in the application, and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being submitted prior to the mailing of a first substantive Office Action in this application, and, therefore, no certification or fee is required (37 C.F.R. § 1.97b(3)). However, should any fees be due, the Commissioner is

authorized to charge such fees to Deposit Account No. 16-1435. A duplicate of this sheet is attached for that purpose.

Respectfully submitted,

Date: 8-2-2005

  
Cynthia B. Rothschild  
Reg. No. 47,040

KILPATRICK STOCKTON LLP  
1001 West Fourth Street  
Winston-Salem, North Carolina 27101-2400  
(336) 747-7541 (Phone)  
(336) 734-2610 (Facsimile)

55474-294389  
WINLIB01:1140936.1

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 12

**Complete if Known**

Application Number	10/718,955
Filing Date	November 21, 2003
First Named Inventor	Clayton H. Johnson et al.
Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	55474-294389

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	1.	US- 4,946,777	08-07-1990	Lam��ris et al.	
	2.	US- 5,242,800	09-07-1993	Jimenez et al.	
	3.	US- 5,324,632	06-28-1994	Weisberg et al.	
	4.	US- 5,352,579	10-04-1994	Milliman	
	5.	US- 5,360,732	11-01-1994	Berka et al.	
	6.	US- 5,360,901	11-01-1994	Berka et al.	
	7.	US- 5,580,971	12-03-1996	Mitsuhasi	
	8.	US- 5,693,501	12-02-1997	Lee et al.	
	9.	US- 5,707,802	01-13-1998	Sandhu et al.	
	10.	US- 5,763,169	06-09-1998	Sandhu et al.	
	11.	US- 5,919,617	07-06-1999	Bhattacharjee et al.	
	12.	US- 5,994,066	11-30-1999	Bergeron et al.	
	13.	US- 5,997,912	12-07-1999	Schlesinger et al.	
	14.	US- 6,001,564	12-14-1999	Bergeron et al.	
	15.	US- 6,117,641	09-12-2000	Berlin et al.	
	16.	US- 6,180,339	01-30-2001	Sandhu et al.	
	17.	US- 6,228,575	05-08-2001	Gingeras et al.	
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	18.	WO 96/21741	07-18-1996	Sandhu et al.		
	19.	WO 99/55874	11-04-1999	Zancope-Oliveria et al.		
	20.	WO 99/54508	10-28-1999	Schafer et al.		
	21.	WO 98/46738	10-22-1998	Weil et al.		
	22.	EP 804619 ABSTRACT	11-05-1997	Sandhu et al.	See: Same as WO96/21741 & US 5,707,802	
	23.	EP 0272009	06-22-1988	Hogan et al.		

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 12

**Complete if Known**

Application Number	10/718,955
Filing Date	November 21, 2003
First Named Inventor	Clayton H. Johnson et al.
Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	55474-294389

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	24.	AMPEL, "Emerging Disease Issues and Fungal Pathogens Associated with HIV Infection," Emerg. Infect. Dis., 2:109-116, 1996	
	25.	ALTSCHUL, S., "Basic Local Alignment Search Tool," J. Mol. Biol., 215: 403-410, 1990	
	26.	AUSUBEL, F.M. et al., Short Protocols in Molecular Biology, 4 <sup>th</sup> Ed., Chapter 2, John Wiley & Sons, N.Y	
	27.	BEAMAN, B. L. et al., "Purification and Properties of a Unique Superoxide Dismutase from Nocardia Asteroides," J. Biol. Chem., 258:91-96, 1983	
	28.	BIRD, R. et al., "Single-Chain Antigen-Binding Proteins," Science, 242:423-426, 1988	
	29.	BROADDUS et al., "Bronchoalveolar Lavage and Transbronchial Biopsy for the Diagnosis of Pulmonary Infections in the Acquired Immunodeficiency Syndrome," Ann. Intern. Med., 102(6):747-752, June 1985	
	30.	BRUMMER et al., "Antifungal Mechanisms of Activated Murine Bronchoalveolar or Peritoneal Macrophages for Histoplasma Capsulatum," Clin. Exp. Immunol., 102(1):65-70, October 1995	
	31.	BULLOCK, W. E. et al., "Role of the Adherence-Promoting Receptors, CR3, LFA-1, and p150,95, in Binding of Histoplasma Capsulatum by Human Macrophages," Journal of Experimental Medicine, 165:195-210, 1987	
	32.	CASTRO et al., "1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS among Adolescents and Adults," MMRW 41:1-14, 1992	
	33.	CHOMCZYNSKI, P. et al., "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction," Anal. Biochem., 162:156-159, 1987	
	34.	CHURCH, G.M. et al., "Genomic Sequencing," Proc. Natl. Acad. Sci., USA, 81:1991-1995, 1984	
	35.	COCKERILL, F.R. et al., "Rapid-Cycle Real-Time PCR: a Revolution for Clinical Microbiology," ASM News, 68:77-83, 2002	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 12

**Complete if Known**

Application Number	10/718,955
Filing Date	November 21, 2003
First Named Inventor	Clayton H. Johnson et al.
Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	55474-294389

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	36.	COHEN et al., "Sequence of the Saccharomyces Cerevisiae CTA1 Gene and Amino Acid Sequence of Catalase A Derived from It," Eur. J. Biochem., 176(1):159-163, September 1988	
	37.	COHEN et al., "Isolation of the Catalase A Gene of Saccharomyces Cerevisiae by Complementation of the ctal Mutation," Mol. Gen. Genet., 200(1):74-79, 1985	
	38.	CORPET, F., "Multiple Sequence Alignment with Hierarchical Clustering," Nucl Acids Res. 16(22), 10881-10890, 1988	
	39.	CROWELE, A. J. et al., "Evidence that Vesicles Containing Living, Virulent Mycobacterium Tuberculosis or Mycobacterium Avium in Cultured Human Macrophages Are Not Acidic," Infect. Immun., 59:1823-1831, 1991	
	40.	DAVIES et al., "Disseminated Histoplasmosis in Immunologically Suppressed Patients," Am. J. Med., 64:94-100, 1978	
	41.	DEEPE, G. S., "The Immune Response to Histoplasma Capsulatum: Unearthing Its Secrets," J. Lab. Clin. Med., 123:201-205, 1998	
	42.	DeGROOTE, M. A. et al., "Periplasmic Superoxide Dismutase Protects Salmonella from Products of Phagocyte NADPH-Oxidase and Nitric Oxide Synthase," Proc. Natl. Acad. Sci. (USA), 94:13997-14001, 1997	
	43.	DERETIC, V. et al., "Mycobacterium Tuberculosis Phagosome," Mol. Microbiol., 31:1603-1609, 1999	
	44.	DESAI et al., "Killing of Histoplasma Capsulatum by Macrophage Colony Stimulating Factor-Treated Human Monocyte-Derived Macrophages: Role for Reactive Oxygen Intermediates," J. Med. Microbiol., 43(3):224-229, September 1995	
	45.	EISSENBERG, L. G. et al., "The Interplay between Histoplasma Capsulatum and Its Host Cells," Vol. I, Ch. 6, W. B. Saunders Company, Ltd. London, UK, 1994	
	46.	EISSENBERG, L. G. et al., "Histoplasma Capulatum Modulates the Acidification of Phagolysosomes," J. Exp. Med., 177:1605-1611, 1993	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

12

**Complete if Known**

Application Number	10/718,955
Filing Date	November 21, 2003
First Named Inventor	Clayton H. Johnson et al.
Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	55474-294389

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	47.	EVARD et al., "The Cyanelle Genome of Cyanophora Paradoxa, Unlike the Chloroplast Genome, Codes for the Ribosomal L3 Protein," Nucleic Acid Res., 18:1115-1119, 1990	
	48.	FANG, F. C. et al., "Virulent Salmonella Typhimurium Has Two Periplasmic Cu, Zn-Superoxide Dismutases," Proc. Natl. Acad. Sci. (USA), 96:7502-7507, 1999	
	49.	FRUGOLI, J. A. et al., "Catalase Is Encoded by a Multigene Family in Arabidopsis thaliana (L.) Heynh," Plant Physiol., 112:327-336, 1996	
	50.	FRUGOLI, J. A. et al., "Intron Loss and Gain during Evolution of the Catalase Gene Family in Angiosperms," Genetics, 149:355-365, 1998	
	51.	GARCIA, E. et al., "Molecular Characterization of KatY (Antigen 5), a Thermoregulated Chromosomally Encoded Catalase-Peroxidase of Yersinia Pestis," J. Bacteriol., 181:3114-3122, 1999	
	52.	GEORGE et al., "Radioimmunoassay: A Sensitive Screening Test for Histoplasmosis and Blastomycosis," Am. Rev. Respir. Dis., 124(4):407-10, October 1981	
	53.	GOFFEAU, A. et al., "Life with 6000 Genes," Science, 274:563-567	
	54.	GOODWIN, R. A. et al., "Histoplasmosis in Normal Hosts," Medicine (Baltimore), 60:231-266, 1981	
	55.	GOODWIN, R. A., Jr. et al., "Disseminated Histoplasmosis: Clinical and Pathologic Correlations," Medicine, 59:1-33, 1980	
	56.	GUAN, L. et al., "Molecular Evolution of Maize Catalases and Their Relationship to Other Eukaryotic and Prokaryotic Catalases," J. Mol. Evol., 42:570-579, 1996	
	57.	HAMILTON, A.J. et al., "Evidence That the M Antigen of Histoplasma Capsulatum var. Capsulatum Is a Catalase Which Exhibits Cross-Reactivity with Other Dimorphic Fungi," J. Med. Vet. Mycol., 28:479-485, 1990	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 5 of 12

**Complete if Known**

Application Number	10/718,955
Filing Date	November 21, 2003
First Named Inventor	Clayton H. Johnson et al.
Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	55474-294389

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	58.	HANSEN et al., "Functional Complementation of Catalase-Defective Peroxisomes in a Methylophilic Yeast by Import of the Catalase A from <i>Saccharomyces Cerevisiae</i> ," <i>Eur. J. Biochem.</i> , 184(1):173-179, September 1989	
	59.	HARTMAN, P. et al., "Immunological Defense Mechanisms in Tuberculosis and MAC-Infection," <i>Diag. Microbiol. Infect. Dis.</i> , 34:147-152, 1999	
	60.	HENIKOFF, S. et al., "Amino Acid Substitution Matrices from Protein Blocks," <i>Proc. Natl. Acad. Sci. USA</i> , 89, 10915-10919, 1992	
	61.	HOCHMAN et al., "Purification and Characterization of a Catalase-Peroxidase and a Typical Catalase from the Bacterium <i>Klebsiella Pneumoniae</i> ," <i>Biochim. Biophys. Act.</i> , 1077(3):299-307, April 1991	
	62.	HOWARD, "Studies on the Catalase of <i>Histoplasma Capsulatum</i> ," <i>Infect. Immun.</i> , 39(3):1161-1166, March 1983	
	63.	HOWARD, "Comparative Sensitivity of <i>Histoplasma Capsulatum</i> Conidiospores and Blastospores to Oxidative Antifungal Systems," <i>Infect. Immun.</i> , 32(1):381-387, April 1981	
	64.	IZAWA et al., "Importance of Catalase in the Adaptive Response to Hydrogen Peroxide: Analysis of Acatalsaeemic <i>Saccharomyces Cerevisiae</i> ," <i>Biochem. J.</i> , 320(Pt.1):61-67, November 15, 1996	
	65.	JACOBSON et al., "Reevaluation of Diagnostic <i>Histoplasma</i> Serologies," <i>Am. J. Med. Sci.</i> , 281(3): 143-51, June 1981	
	66.	JEAVONS, L. et al. "Identification and Purification of Specific <i>Penicillium Marneffe</i> Antigens and Their Recognition by Human Immune Sera," <i>J. Clin. Microbiol.</i> , 36:949-954, 1998	
	67.	JOHNSON, C. et al., "The Catalase Isozymes and Genes of <i>Histoplasma Capsulatum</i> ," Abstract #361, XXI Fungal Genetics Conference, at <a href="http://www.fgsc.net/fungalgenetics2001/generega.htm">http://www.fgsc.net/fungalgenetics2001/generega.htm</a> , Asilomar, CA, March 2001	
	68.	JOHNSON, C. et al., "Investigation of the Catalase Enzyme of <i>Histoplasma Capsulatum</i> ," <i>Fed. Res. Prog.</i> , Abstract 0001:598, January 1997	
	69.	JOHNSON et al., "Differentially Expressed Catalase Genes in <i>Histoplasma Capsulatum</i> ," Abstract F-65, Abstracts of the General Meeting of the Amer. Soc. Microbiol., 98:263-64, 1998	
	70.	JOHNSON, C. H. et al., "Redundancy, Phylogeny and Differential Expression of <i>Histoplasma Capsulatum</i> Catalases," <i>Microbiology</i> , 148:1129-1142, 2002	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 6 of 12

**Complete if Known**

Application Number	10/718,955
Filing Date	November 21, 2003
First Named Inventor	Clayton H. Johnson et al.
Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	55474-294389

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	71.	JOHNSON, C. et al., "Catalase Isozymes and Genes of Histoplasma Capsulatum," Abstract I-73, Abstracts of the Amer. Soc. for Microbiol., 100:397, 2000	
	72.	JOHNSON, C. H. et al., "Isolation of a Histoplasma Capsulatum cDNA that Complements a Mitochondrial NAD(+)-Isocitrate Dehydrogenase Subunit I-Deficient Mutant of Saccharomyces Cerevisiae," Yeast, 15:799-804, 1999	
	73.	JOHNSON, et al., "Characterization of the Differentially Expressed Catalase Isozymes and Genes of Histoplasma Capsulatum," Abstracts of the General Meeting of the Amer. Soc. Microbiol., 99:298-299, 1999	
	74.	JOHNSON, C.H. et al., "The psbB Gene Cluster of the Chlamydomonas Reinhardtii Chloroplast: Sequence and Transcriptional Analysis of psbN and psbH," Plant Mol. Biol., 22:645-658, 1993	
	75.	JOHNSON, S. M. et al., "Preparation and ELISA Evaluation of Blastomyces Dermatitidis Yeast Phase Lysate Antigens," Diagn. Microbiol. Infect. Dis., 11(2):81-86, October 1998	
	76.	KAMEI et al., "Induction of Stress Protein Synthesis in Histoplasma Capsulatum by Heat, Low pH and Hydrogen Peroxide," J. Med. Vet. Mycol., 30(5):385-393, 1992	
	77.	KASUGA, T. et al., "Phylogenetic Relationships of Varieties and Geographical Groups of the Human Pathogenic Fungus Histoplasma Capsulatum Darling," J. Clin. Micro., 37:653-663, 1999	
	78.	KAWASAKI et al., "Two Divergent Catalase Genes Are Differentially Regulated during Aspergillus Nidulans Development and Oxidative Stress," J. Bacteriol., 179(10):3284-3292, May 1997	
	79.	KEATH et al., "Typing of Histoplasma Capsulatum by Restriction Fragment Length Polymorphisms in a Nuclear Gene," J. Clin. Microbiol., 30(8):2104-2107, August 1992	
	80.	KERSULYTE et al., "Diversity among Clinical Isolates of Histoplasma Capsulatum Detected by Polymerase Chain Reaction with Arbitrary Primers," J. Bacteriol., 174(22):7075-7079, November 1992	
	81.	KLEIN, et al., "Isolation, Purification, and Radiolabeling of a Novel 120-kD Surface Protein on Blastomyces Dermatitidis Yeasts to Detect Antibody in Infected Patients," J. Clin. Invest., 85(1):152-161, January 1990	
	82.	KLOTZ, M. G., "Catalase Genes Are of Bacterial Origin and Have Evolved in Eukaryotes by Intron Acquisition," American Society for Microbiology, 101 <sup>st</sup> Annual Meeting, Abstract H-18, 2000	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 7 of 12

**Complete if Known**

Application Number	10/718,955
Filing Date	November 21, 2003
First Named Inventor	Clayton H. Johnson et al.
Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	55474-294389

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	83.	KLOTZ, M. G., "On the Molecular Evolution of Catalatic Hydroperoxidases," University of Louisville, KY and University of Manitoba, Winnipeg, MB, Canada	
	84.	KLOTZ, M. G. et al., "Phylogenetic Relationships among Prokaryotic and Eukaryotic Catalases," Mol. Biol. Evol., 14:951-958, 1997	
	85.	KRAGLER et al., "Two Independent Peroxisomal Targeting Signals in Catalase A of Saccharomyces Cerevisiae," J. Cell. Biol., 120(3):665-673, February 1993	
	86.	KURITA, N. et al., "Resistance of Histoplasma Capsulatum to Killing by Human Neutrophils," Mycopathologia, 115:207-213, 1991	
	87.	LARDINOIS et al., "Characterization of Hydrogen Peroxide and Superoxide Degrading Pathways of Aspergillus Niger Catalase: A Steady-State Analysis," Free Radic. Res., 20(1):29-50, January 1994	
	88.	LEUTENEGGER, C.M. et al., "Real-Time TaqMan PCR as a Specific and More Sensitive Alternative to the Branched-chain DNA Assay for Quantitation of Simian Immunodeficiency Virus RNA," AIDS Res. Hum. Retroviruses, 17:243-251, 2001	
	89.	LI, R-K et al., "In Vitro Activities of Voriconazole, Intracozazole, and Amphotericin B against Blastomyces Dermatitidis, Coccidioides Immitis, and Histoplasma Capsulatum," Antimicrobial Agents and Chemotherapy, 44:1734-1736, 2000	
	90.	LI, et al., "Expression of katG in Mycobacterium tuberculosis Is Associated with Its Growth and Persistence in Mice and Guinea Pigs," J. Infect. Dis., 177:1030-1035, 1998	
	91.	LOEWEN, P.C. et al., "Catalase - and "Old" Enzyme That Continues to Surprise Us," ASM News, 66:76-82, 2002	
	92.	LOPEZ-Medrano, R., "An Immunodominant 90-Kilodalton Aspergillus Fumigatus Antigen Is the Subunit of a Catalase," Infection & Immunity, 63:4774-4780, 1995	
	93.	MA et al., "Bacterioferritin A Modulates Catalase A (KatA) Activity and Resistance to Hydrogen Peroxide in Pseudomonas Aeruginosa," J. Bacteriol., 181(12):3730-3742, June 1999	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 8 of 12

**Complete if Known**

Application Number	10/718,955
Filing Date	November 21, 2003
First Named Inventor	Clayton H. Johnson et al.
Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	55474-294389

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	94.	MANGALA, A.N. et al., "Determination of Bacterial Load by Real-time PCR Using a Broad-Range (universal) Probe and Primers Set," Microbiology 148, 257-266, 2002	
	95.	MARCHLER, G. et al., "A Saccharomyces Cerevisiae Element Controlled by Protein Kinase A Activates Transcription in Response to a Variety of Stress Conditions," UAS EMBO Journal, 12:1997-2003, 1993	
	96.	MARESCA et al., "Morphological Transitiion in the Human Fungal Pathogen Histoplasma Capsulatum," Trends Microbiol., 2:110-114, 1994	
	97.	MARESCA, B. et al., "Respiration in the Yeast and Mycelial Phases of Histoplasma Capsulatum," Journal of Bacteriology, 138:647-649, 1979	
	98.	MIYASHIRO et al., "Immunofluorescent Detection of Histoplasma Capsulatum in Primate Experimental Ocular Histoplasmosis," Curr. Eye. Res., 5(11):833-840, November 1986	
	99.	MUNRO, C. A. et al., "Chitin Synthesis in Human Pathogenic Fungi," Medical Mycology, 39 (S1), 41-53, 2001	
	100.	MURRAY, et al., "Nucleotide Sequence of Peroxisomal Catalase from the Yeast Candida Tropicalis pK223; Identification of an Upstream BamHI Site Polymorphism," Nucleic Acids Res., 17(9):3600, May 1989	
	101.	MURRAY, et al., "The Nucleotide Sequence of Complementary DNA and the Deduced Amino Acid Sequence of Peroxisomal Catalase of the Yeast Candida Tropicalis pK223," Gene, 61(3):401-413, 1987	
	102.	NADKARNI, M.A. et al., "Determination of Bacterial Load by Real-Time PCR Using a Broad-Range (Universal) Probe and Primers Set," Microbiology, 148:257-266, 2002	
	103.	NAVARRO et al., "Posttranscriptional Control Mediates Cell Type-Specific Localization of Catalase A During Aspergillus Nidulans Development," J. Bacteriol., 180(21):5733-5738, November 1998	
	104.	NEWMAN, S. L. et al., "Phagocytosis of Histoplasma Capsulatum Yeasts and Microconidia by Human Cultured Macrophages and Alveolar Macrophages," Journal of Clinical Investigation, 85:223-230, 1990	
	105.	NEWMAN, S. L. et al., "Digestion of Histoplasma Capsulatum Yeasts by Human Macrophages," J. Immunol., 149:574-580, 1992	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 9 of 12

**Complete if Known**

Application Number	10/718,955
Filing Date	November 21, 2003
First Named Inventor	Clayton H. Johnson et al.
Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	55474-294389

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	106.	NEWMAN, S. L. et al., "Human Neutrophil-Mediated Fungistasis Against Histoplasma Capsulatum," J. Clinical Investigation, 92:624-631, 1993	
	107.	NEWMAN, S. L., "Macrophages in Host Defense Against Histoplasma Capsulatum," Trends Microbiol., 7:67-71, 1999	
	108.	OKADA et al., "Catalase Gene of Yeast Candida Tropicalis: Sequence Analysis and Comparison with Peroxisomal and Cytosolic Catalases from Other Sources," Eur. J. Biochem., 170(1-2):105-10, December 1987	
	109.	PADHYE et al., "Comparative Evaluation of a Chemiluminescent DNA Probe and an Exoantigen Test for Rapid Identification of Histoplasma Capsulatum," J. Clin. Microbiol., 30(12):3108-3111, December 1992	
	110.	PATRIARCA, E. J. et al., "Mitochondrial Activity and Heat-Shock Response During Morphogenesis in the Pathogenic Fungus Histoplasma Capsulatum," Biochemistry & Cell Biology, 70:207-214, 1992	
	111.	PITKIN, J. W., et al., "A Putative Cyclic Peptide Efflux Pump Encoded by the TOXA Gene of the Plant-Pathogenic Fungus Cochliobolus Carbonum," Microbiology, 142:1557-1565, 1996	
	112.	RADCLIFF et al., "Catalase, a Novel Antigen for Helicobacter Pylori Vaccination," Infect. Immun., 65(11):4668-4674, November 1997	
	113.	RAMBUKKANA, A. et al., "Identification of a Novel 17-kDA Protein from Mycobacterium Tuberculosis Culture Fluid by a Monoclonal Antibody Specific for the Mycobacterium Tuberculosis Complex," Scand. J. Immunol., 37:471-478, 1993	
	114.	RAYNAUD, C. et al., "Extracellular Enzyme Activities Potentially Involved in the Pathogenicity of Mycobacterium Tuberculosis," Microbiology, 144:577-587, 1998	
	115.	REID et al., "Direct Detection of Histoplasma Capsulatum in Soil Suspensions by Two-Stage PCR," Mol. Cell. Probes, 13(4):269-273, August 1999	
	116.	REISS, et al., "Non-Culture Based Diagnostic Tests for Mycotic Infections," Med. Mycol., 38(1):147-159, 2000	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 10 of 12

**Complete if Known**

Application Number	10/718,955
Filing Date	November 21, 2003
First Named Inventor	Clayton H. Johnson et al.
Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	55474-294389

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	117.	ROUSE, D. A. et al., "Molecular Mechanisms of Isoniazid Resistance in Mycobacterium Tuberculosis and Mycobacterium Bovis," Infect. Immun., 63:1427-1433, 1995	
	118.	SAMBROOK, et al., "Molecular Cloning: A Laboratory Manual," Cold Spring Harbor Laboratory Press, 1989, Chapter 9	
	119.	SCHAFFNER, A. et al., "In Vitro Susceptibility of Fungi to Killing by Neutrophil Granulocytes Discriminates between Primary Pathogenicity and Opportunism," J. Clin. Invest., 78:511-524, 1986	
	120.	SCHAFFNER, A. et al., "Killing of Aspergillus Spores Depends on the Anatomical Source of the Macrophage," Infect. Immun., 42:1109-1115, 1983	
	121.	SCHAFFNER, A. et al., "Selective Protection against Conidia by Mononuclear and against Mycelia by Polymorphonuclear Phagocytes in Resistance to Aspergillus," J. Clin. Invest., 69:617-631, 1982	
	122.	SCHERR, G. H. et al., "Studies on the Dimorphism of Histoplasma Capsulatum," Exp. Cell Res., 12:92-107, 1957	
	123.	SCHERR & Weaver, "The Dimorphism Phenomenon in Yeasts," Bact. Rev., 17:51-92, 1953	
	124.	SCHNUR, R. A. et al., "The Respiratory Burst Response to Histoplasma Capsulatum by Human Neutrophils," Journal of Immunology, 144:4765-4772, 1990	
	125.	SHERMAN, D. R. et al., "Compensatory ahpC Gene Expression in Isoniazid-Resistant Mycobacterium Tuberculosis," Science, 272:1641-1643, 1996	
	126.	SONNENBERG, M. G. et al., "Definition of Mycobacterium Tuberculosis Culture Filtrate Proteins by Two-Dimensional Polyacrylamide Gel Electrophoresis, N-Terminal Amino Acid Sequencing, and Electrospray Mass Spectrometry," Infect. Immun., 65:4515-4524, 1997	
	127.	SPIEGELHALDER, C. B. et al., "Purification of Helicobacter Pylori Superoxide Dismutase and Cloning and Sequencing of the Gene," Infect. Immun., 61:5315-5325, 1993	
	128.	SPITZER et al., "Use of Mitochondrial and Ribosomal DNA Polymorphisms to Classify Clinical and Soil Isolates of Histoplasma Capsulatum," Infect. Immun., 57:1409-1412, May 1989	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 11 of 12

**Complete if Known**

Application Number	10/718,955
Filing Date	November 21, 2003
First Named Inventor	Clayton H. Johnson et al.
Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	55474-294389

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	129.	STEIN, D.K. et al., "Fungal Infections in the Immunocompromised Host," Diagn. Microbiol., Infect., Dis., 12:221S-228S, 1989	
	130.	STORZ, G. et al., "OxyR: A Regulator of Antioxidant Genes," J. Nutr., 122:627-30, 1992	
	131.	STORZ, G. et al., "The OxyR Regulon," Antonie Van Leeuwenhoek, 58:157-161, 1990	
	132.	STORZ, G. et al., "Transcriptional Regulator of Oxidative Stress-Inducible Genes: Direct Activation by Oxidation," Science, 248:189-194, 1990	
	133.	STORZ, G. et al., "Bacterial Defenses against Oxidative Stress," Trends Genet., 6:363-368, 1990	
	134.	STRASSER, J. E. et al., "Regulation of the Macrophage Vacuolar ATPase and Phagosome-Lysosome Fusion by Histoplasma Capsulatum," J. Immunol., 162:6148-6154, 1999	
	135.	STURGILL-KOSZYCKI, S., et al., "Lack of Acidification in Mycobacterium Phagosomes Produced by Exclusion of the Vesicular Proton-ATPase," Science, 263:678-681, 1994	
	136.	THOMSON, J.M. et al., "pMECA: A Cloning Plasmid with 44 Unique Restriction Sites that Allows Selection of Recombinants Based on Colony Size," Biotechniques, 24, 922-927, 1998	
	137.	THOMPSON, J.D. et al., "CLUSTAL W: Improving the Sensitivity of Progressive Multiple Sequence Alignment through Sequence Weighting, Position-Specific Gap Penalties and Weight Matrix Choice," Nucleic Acids Res., 22:4673-4680, 1994	
	138.	VERA-CABRERA, L. et al., "Distribution of a Nocardia Brasiliensis Catalase Gene Fragment in Members of the Genera Nocardia, Gordonia, and Rhodococcus," J. Clin. Microbiol., 37:1971-1976, 1999	
	139.	WALL, S.J et al., "Quantitative Reverse Transcription—Polymerase Chain Reaction (RT-PCR): A Comparison of Primer-Dropping, Competitive, and Real-time RT-PCRs," Anal. Biochem., 300:269-273, 2002	
	140.	WHEAT et al., "Risk Factors for Disseminated or Fatal Histoplasmosis," Ann. Intern. Med., 96:159-163, 1982	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 12 of 12

**Complete if Known**

Application Number	10/718,955
Filing Date	November 21, 2003
First Named Inventor	Clayton H. Johnson et al.
Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	55474-294389

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	141.	WHEAT et al., "Histoplasmosis in the Acquired Immune Deficiency Syndrome," Am. J. Med., 78:203-210, 1985	
	142.	WILSON, T. M. et al., "Effect of inhA and katG on Isoniazid Resistance and Virulence of Mycobacterium Bovis," Mol. Microbiol., 15:1009-1015, 1995	
	143.	WOODS et al., "Fast DNA Isolation from Histoplasma Capsulatum: Methodology for Arbitrary Primer Polymerase Chain Reaction-Based Epidemiological and Clinical Studies," J. Clin. Microbiol., 31(2):463-464, February 1993	
	144.	WOODS, J.P. et al., "InVivo Generation of Linear Plasmids with Addition of Telomeric Sequences by Histoplasma Capsulatum," Molecular Microbiology, 6:3603-3610, 1992	
	145.	WORSHAM, P.L. et al., "Quantitative Plating of Histoplasma Capsulatum Without Addition of Conditioned Medium or Siderophores," J. Med. & Veterinary Mycology, 26:137-143, 1998	
	146.	ZAMOCKY et al., "Site-Directed Mutagenesis of the Lower Parts of the Major Substrate Channel of Yeast Catalase A Leads to Highly Increased peroxidatic Activity," FEBS Lett., 367(3):241-245, July 1995	
	147.	ZANCOPE-OLIVERIA et al., "Molecular Cloning, Characterization, and Expression of the M Antigen of Histoplasma Capsulatum," Infect. Immun., 67(4):1947-1953, April 1999	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.